Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI
Open Access
- 16 January 2016
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 37 (7) , 9367-9374
Abstract
An attempt was made to compare the usefulness of determining markers carcinoembryonic antigen (CEA) and tumor-associated trypsin inhibitor (TATI) in endometrial cancer patients in whom recurrence or distant metastasis was diagnosed in observation after treatment. The study included 316 patients aged 32–81, average age of 61 years, SD = 8.72, with diagnosed endometrial cancer, treated between 1994 and 1995 at the Oncology Center in Warsaw and then under observation from 4 months to 17 years after completion of treatment. The levels of the markers TATI and CEA were assessed from the first five serum samples taken during postoperative radiotherapy and in the initial period of observation after completed treatment. Receiver operating characteristic (ROC) curves were generated, determining the sensitivity and specificity of both CEA and TATI in patients who experienced treatment failure, i.e., recurrence and distant metastasis. Assessing the sensitivity of the marker CEA, it was found that if in the third sample, i.e., during radiation therapy, the marker level increased by more than 20 % compared with the first sample, then recurrence of cancer occurred during the observation period in 75.9 % of patients and metastatic occurred in 69.7 % of patients. In the evaluation of the marker TATI, it was found that if the level of TATI between the first and the third sample increases by 10.6 % from the initial level, then in 84.4 % (sensitivity) of cases, this means the occurrence of cancer recurrence and in 75.7 % (sensitivity) of cases, the occurrence of metastasis. The specificity of both markers is low and not useful diagnostically.Keywords
This publication has 34 references indexed in Scilit:
- Serum Biomarkers for Early Detection of Gynecologic CancersCancers, 2010
- High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancerBritish Journal of Cancer, 2009
- Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian CancerClinical Cancer Research, 2004
- Tumor-Associated Trypsinogen-2 (Trypsinogen-2) Activates Procollagenases (MMP-1, -8, -13) and Stromelysin-1 (MMP-3) and Degrades Type I CollagenBiochemistry, 2003
- Clinical utility of biochemical markers in colorectal cancerEuropean Journal of Cancer, 2003
- Serum tumour markers CA 15-3, TPA, TPS, hCG β and TATI in the monitoring of chemotherapy response in metastatic breast cancerScandinavian Journal of Clinical and Laboratory Investigation, 2001
- Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screeningCancer, 1993
- Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in gynecologic tumorsGynecologic Oncology, 1989
- Prognostic value of CEA and ferritin assay in breast cancer: A multivariate analysisEuropean Journal of Cancer and Clinical Oncology, 1988
- Excretion of a tumor‐associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancyInternational Journal of Cancer, 1983